MedTrace Logo

Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001

NCT01494922 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2021-08-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to provide subjects who participated in prior studies of EXC 001 the opportunity to have their hypertrophic scars surgically revised and treated with EXC 001.

Conditions

  • Reduction in Severity of Skin Scarring

Interventions

DRUG

EXC 001 (currently called PF-06473871)

Single dose administered by injection at four different times

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-08
Primary Completion
2013-09-10
Completion
2013-09-10

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01494922 on ClinicalTrials.gov